Detailed Narrative
Guidance Raise and Outlook
Ingersoll Rand raised its full-year guidance for revenue, adjusted EBITDA, and adjusted EPS, with the adjusted EBITDA midpoint now at $2.13 billion and adjusted EPS at $3.40. This raise is attributed to strong first-half organic order growth of low single digits, a book-to-bill of 1.06x, and a 16% increase in total backlog since year-end 2024. The company expects organic volume growth to improve from mid-single-digit declines in H1 to low single-digit declines in H2, with pricing in the 3.5%-4% range.
M&A Strategy and Recent Acquisitions
The company continues its M&A-led growth strategy, having closed 11 transactions year-to-date, adding over $200 million in annualized revenue at a 9.5x pre-synergy EBITDA multiple. Two recent acquisitions, Lead Fluid (peristaltic pump technology for life sciences) and Termomeccanica Industrial Compressors (core bolt-on), were highlighted, both acquired at low double-digit pre-synergy adjusted EBITDA multiples and expected to achieve mid-teens ROIC by year three. The company has another 8 deals under LOI.
Sustainability and Value Creation
Ingersoll Rand was ranked #1 in North America and globally in its industry on the Dow Jones Best-in-class Indices for the third consecutive year and earned a spot on CDP's A list. The company emphasizes its ownership mindset and IRX culture as catalysts for long-term performance, driving approximately $600 million in value creation for employees through equity grants since the Gardner Denver IPO.
Demand and Order Cadence
Organic orders were up low single digits in H1, with Q2 orders up 8% YoY and 3% sequentially. The book-to-bill was 1.03x in Q2. Management noted stable demand throughout Q2 and into July, with continued strength in large, long-cycle orders, particularly in IT&S. Regional performance showed strong orders in Americas (high teens), EMEA (high single digits), and Asia Pacific (low double digits), including organic growth in China.
ILC Dover Impairment and M&A Discipline
The company recorded a non-cash goodwill and asset impairment related to its High Pressure Solutions business and ILC Dover. For ILC Dover, this was due to reduced expectations for a specific aerospace and defense customer (related to the International Space Station) and market-based inputs (increased discount rate, peer multiple contraction) affecting the Biopharma business and trade name. Management reiterated conviction in the long-term prospects of the Life Sciences business and confirmed filing an insurance claim under the reps and warranties policy for the ILC Dover transaction.
Segment Performance Overview
IT&S orders were up 7% YoY (5% sequentially), with low single-digit organic growth and a 1.05x book-to-bill. P&ST orders were up 13% YoY, with organic orders down 5% (but up low single digits excluding large long-cycle orders from prior year). P&ST adjusted EBITDA margin improved sequentially and YoY, reaching 29.5%.
Capital Allocation
Free cash flow for Q2 was $210 million, with year-to-date FCF up 13%. Total liquidity stands at $3.9 billion, and leverage improved to 1.7 turns. The company deployed $500 million to share repurchases in Q2 (6.1 million shares at $81.35 average price) and plans up to an additional $250 million for the balance of the year, while prioritizing M&A.